ID   ARSA_HUMAN              Reviewed;         507 AA.
AC   P15289; B2RCA6; B7XD04; F8WCC8; Q6ICI5; Q96CJ0;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1991, sequence version 3.
DT   10-MAY-2017, entry version 194.
DE   RecName: Full=Arylsulfatase A;
DE            Short=ASA;
DE            EC=3.1.6.8;
DE   AltName: Full=Cerebroside-sulfatase;
DE   Contains:
DE     RecName: Full=Arylsulfatase A component B;
DE   Contains:
DE     RecName: Full=Arylsulfatase A component C;
DE   Flags: Precursor;
GN   Name=ARSA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2562955;
RA   Stein C., Gieselmann V., Kreysing J., Schmidt B., Pohlmann R.,
RA   Waheed A., Meyer H.E., O'Brien J.S., von Figura K.;
RT   "Cloning and expression of human arylsulfatase A.";
RL   J. Biol. Chem. 264:1252-1259(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1975241; DOI=10.1111/j.1432-1033.1990.tb19167.x;
RA   Kreysing J., von Figura K., Gieselmann V.;
RT   "Structure of the arylsulfatase A gene.";
RL   Eur. J. Biochem. 191:627-631(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=19262745;
RA   Oshikawa M., Usami R., Kato S.;
RT   "Characterization of the arylsulfatase I (ARSI) gene preferentially
RT   expressed in the human retinal pigment epithelium cell line ARPE-19.";
RL   Mol. Vis. 15:482-494(2009).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   SER-391.
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LEU-82; CYS-193;
RP   SER-350; VAL-356; SER-391; SER-440 AND HIS-496.
RG   NIEHS SNPs program;
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   SER-391.
RC   TISSUE=B-cell;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 19-33 AND 434-479, AND SUBUNIT.
RX   PubMed=1352993; DOI=10.1016/0167-4838(92)90132-W;
RA   Fujii T., Kobayashi T., Honke K., Gasa S., Ishikawa M., Shimizu T.,
RA   Makita A.;
RT   "Proteolytic processing of human lysosomal arylsulfatase A.";
RL   Biochim. Biophys. Acta 1122:93-98(1992).
RN   [10]
RP   PARTIAL PROTEIN SEQUENCE, IDENTIFICATION BY MASS SPECTROMETRY,
RP   OXOALANINE AT CYS-69, AND LACK OF OXOALANINE IN MSD.
RX   PubMed=7628016; DOI=10.1016/0092-8674(95)90314-3;
RA   Schmidt B., Selmer T., Ingendoh A., von Figura K.;
RT   "A novel amino acid modification in sulfatases that is defective in
RT   multiple sulfatase deficiency.";
RL   Cell 82:271-278(1995).
RN   [11]
RP   INVOLVEMENT IN MSD.
RX   PubMed=15146462; DOI=10.1002/humu.20040;
RA   Cosma M.P., Pepe S., Parenti G., Settembre C., Annunziata I.,
RA   Wade-Martins R., Domenico C.D., Natale P.D., Mankad A., Cox B.,
RA   Uziel G., Mancini G.M., Zammarchi E., Donati M.A., Kleijer W.J.,
RA   Filocamo M., Carrozzo R., Carella M., Ballabio A.;
RT   "Molecular and functional analysis of SUMF1 mutations in multiple
RT   sulfatase deficiency.";
RL   Hum. Mutat. 23:576-581(2004).
RN   [12]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-158 AND ASN-350.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS), AND OLIGOMERIZATION.
RX   PubMed=9521684; DOI=10.1021/bi9714924;
RA   Lukatela G., Krauss N., Theis K., Selmer T., Gieselmann V.,
RA   von Figura K., Saenger W.;
RT   "Crystal structure of human arylsulfatase A: the aldehyde function and
RT   the metal ion at the active site suggest a novel mechanism for sulfate
RT   ester hydrolysis.";
RL   Biochemistry 37:3654-3664(1998).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS), AND MUTAGENESIS OF CYS-69.
RX   PubMed=11124905; DOI=10.1006/jmbi.2000.4297;
RA   von Buelow R., Schmidt B., Dierks T., von Figura K., Uson I.;
RT   "Crystal structure of an enzyme-substrate complex provides insight
RT   into the interaction between human arylsulfatase A and its substrates
RT   during catalysis.";
RL   J. Mol. Biol. 305:269-277(2001).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS) OF 19-507, SUBUNIT,
RP   GLYCOSYLATION AT ASN-158 AND ASN-184, ACTIVE SITE, ENZYME REGULATION,
RP   CALCIUM-BINDING, AND COFACTOR.
RX   PubMed=12888274; DOI=10.1016/S0162-0134(03)00176-4;
RA   Chruszcz M., Laidler P., Monkiewicz M., Ortlund E., Lebioda L.,
RA   Lewinski K.;
RT   "Crystal structure of a covalent intermediate of endogenous human
RT   arylsulfatase A.";
RL   J. Inorg. Biochem. 96:386-392(2003).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.55 ANGSTROMS) OF 69-73 IN COMPLEX WITH SUMF1.
RX   PubMed=16368756; DOI=10.1073/pnas.0507592102;
RA   Roeser D., Preusser-Kunze A., Schmidt B., Gasow K., Wittmann J.G.,
RA   Dierks T., von Figura K., Rudolph M.G.;
RT   "A general binding mechanism for all human sulfatases by the
RT   formylglycine-generating enzyme.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:81-86(2006).
RN   [17]
RP   REVIEW ON MLD VARIANTS.
RX   PubMed=7866401; DOI=10.1002/humu.1380040402;
RA   Gieselmann V., Zlotogora J., Harris A., Wenger D.A., Morris C.P.;
RT   "Molecular genetics of metachromatic leukodystrophy.";
RL   Hum. Mutat. 4:233-242(1994).
RN   [18]
RP   VARIANT SER-350, ASSOCIATION WITH ARYLSULFATASE A PSEUDODEFICIENCY,
RP   AND CHARACTERIZATION OF VARIANT SER-350.
RX   PubMed=2574462; DOI=10.1073/pnas.86.23.9436;
RA   Gieselmann V., Polten A., Kreysing J., von Figura K.;
RT   "Arylsulfatase A pseudodeficiency: loss of a polyadenylylation signal
RT   and N-glycosylation site.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:9436-9440(1989).
RN   [19]
RP   VARIANT MLD ASP-99.
RX   PubMed=1673291;
RA   Kondo R., Wakamatsu N., Yoshino H., Fukuhara N., Miyatake T.,
RA   Tsuji S.;
RT   "Identification of a mutation in the arylsulfatase A gene of a patient
RT   with adult-type metachromatic leukodystrophy.";
RL   Am. J. Hum. Genet. 48:971-978(1991).
RN   [20]
RP   VARIANT MLD PHE-96.
RX   PubMed=1678251;
RA   Gieselmann V., Fluharty A.L., Toennesen T., von Figura K.;
RT   "Mutations in the arylsulfatase A pseudodeficiency allele causing
RT   metachromatic leukodystrophy.";
RL   Am. J. Hum. Genet. 49:407-413(1991).
RN   [21]
RP   VARIANT MLD LEU-426, AND VARIANTS CYS-193 AND SER-391.
RX   PubMed=1670590; DOI=10.1056/NEJM199101033240104;
RA   Polten A., Fluharty A.L., Fluharty C.B., Kappler J., von Figura K.,
RA   Gieselmann V.;
RT   "Molecular basis of different forms of metachromatic leukodystrophy.";
RL   N. Engl. J. Med. 324:18-22(1991).
RN   [22]
RP   VARIANT MLD GLN-84.
RX   PubMed=1353340; DOI=10.1002/ana.410310305;
RA   Kappler J., von Figura K., Gieselmann V.;
RT   "Late-onset metachromatic leukodystrophy: molecular pathology in two
RT   siblings.";
RL   Ann. Neurol. 31:256-261(1992).
RN   [23]
RP   VARIANT MLD SER-309.
RX   PubMed=8101038;
RA   Kreysing J., Bohne W., Bosenberg C., Marchesini S., Turpin J.C.,
RA   Baumann N., von Figura K., Gieselmann V.;
RT   "High residual arylsulfatase A (ARSA) activity in a patient with late-
RT   infantile metachromatic leukodystrophy.";
RL   Am. J. Hum. Genet. 53:339-346(1993).
RN   [24]
RP   VARIANT MLD ARG-245.
RX   PubMed=8101083; DOI=10.1089/dna.1993.12.493;
RA   Hasegawa Y., Kawame H., Eto Y.;
RT   "Mutations in the arylsulfatase A gene of Japanese patients with
RT   metachromatic leukodystrophy.";
RL   DNA Cell Biol. 12:493-498(1993).
RN   [25]
RP   VARIANT MLD LEU-426.
RX   PubMed=8095918; DOI=10.1007/BF00230227;
RA   Barth M.L., Fensom A., Harris A.;
RT   "Prevalence of common mutations in the arylsulphatase A gene in
RT   metachromatic leukodystrophy patients diagnosed in Britain.";
RL   Hum. Genet. 91:73-77(1993).
RN   [26]
RP   VARIANT MLD SER-122.
RX   PubMed=7902317; DOI=10.1007/BF00216449;
RA   Honke K., Kobayashi T., Fujii T., Gasa S., Xu M., Takamaru Y.,
RA   Kondo R., Tsuji S., Makita A.;
RT   "An adult-type metachromatic leukodystrophy caused by substitution of
RT   serine for glycine-122 in arylsulfatase A.";
RL   Hum. Genet. 92:451-456(1993).
RN   [27]
RP   VARIANTS MLD VAL-212; VAL-224 AND TYR-295.
RX   PubMed=7906588; DOI=10.1093/hmg/2.12.2117;
RA   Barth M.L., Fensom A., Harris A.;
RT   "Missense mutations in the arylsulphatase A genes of metachromatic
RT   leukodystrophy patients.";
RL   Hum. Mol. Genet. 2:2117-2121(1993).
RN   [28]
RP   VARIANT MLD MET-274.
RX   PubMed=8104633; DOI=10.1002/humu.1380020405;
RA   Harvey J.S., Nelson P.V., Carey W.F., Robertson E.F., Morris C.P.;
RT   "An arylsulfatase A (ARSA) missense mutation (T274M) causing late-
RT   infantile metachromatic leukodystrophy.";
RL   Hum. Mutat. 2:261-267(1993).
RN   [29]
RP   VARIANT MLD ILE-409.
RX   PubMed=7909527; DOI=10.1007/BF00201666;
RA   Hasegawa Y., Kawame H., Ida H., Ohashi T., Eto Y.;
RT   "Single exon mutation in arylsulfatase A gene has two effects: loss of
RT   enzyme activity and aberrant splicing.";
RL   Hum. Genet. 93:415-420(1994).
RN   [30]
RP   VARIANTS MLD ASP-86; LEU-96; HIS-190; MET-274 AND TRP-370, AND
RP   CHARACTERIZATION OF VARIANTS MLD ASP-86; LEU-96; HIS-190; MET-274 AND
RP   TRP-370.
RX   PubMed=7825603;
RA   Heinisch U., Zlotogora J., Kafert S., Gieselmann V.;
RT   "Multiple mutations are responsible for the high frequency of
RT   metachromatic leukodystrophy in a small geographic area.";
RL   Am. J. Hum. Genet. 56:51-57(1995).
RN   [31]
RP   VARIANT MLD LEU-136.
RX   PubMed=7860068; DOI=10.1007/BF00209402;
RA   Kafert S., Heinisch U., Zlotogora J., Gieselmann V.;
RT   "A missense mutation P136L in the arylsulfatase A gene causes
RT   instability and loss of activity of the mutant enzyme.";
RL   Hum. Genet. 95:201-204(1995).
RN   [32]
RP   VARIANTS MLD LEU-82; TYR-172; CYS-201; GLN-311; VAL-335 AND TRP-390.
RX   PubMed=7581401; DOI=10.1002/humu.1380060210;
RA   Barth M.L., Fensom A., Harris A.;
RT   "Identification of seven novel mutations associated with metachromatic
RT   leukodystrophy.";
RL   Hum. Mutat. 6:170-176(1995).
RN   [33]
RP   VARIANTS MLD HIS-153 AND VAL-308, AND CHARACTERIZATION OF VARIANTS MLD
RP   HIS-153 AND VAL-308.
RX   PubMed=8891236; DOI=10.1016/0387-7604(96)00041-1;
RA   Tsuda T., Hasegawa Y., Eto Y.;
RT   "Two novel mutations in a Japanese patient with the late-infantile
RT   form of metachromatic leukodystrophy.";
RL   Brain Dev. 18:400-403(1996).
RN   [34]
RP   CHARACTERIZATION OF VARIANTS MET-274 AND VAL-335.
RX   PubMed=8723680;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:4<311::AID-HUMU4>3.0.CO;2-B;
RA   Hess B., Kafert S., Heinisch U., Wenger D.A., Zlotogora J.,
RA   Gieselmann V.;
RT   "Characterization of two arylsulfatase A missense mutations D335V and
RT   T274M causing late infantile metachromatic leukodystrophy.";
RL   Hum. Mutat. 7:311-317(1996).
RN   [35]
RP   VARIANT MLD PRO-428.
RX   PubMed=9272717;
RA   Regis S., Filocamo M., Stroppiano M., Corsolini F., Gatti R.;
RT   "A T > C transition causing a Leu > Pro substitution in a conserved
RT   region of the arylsulfatase A gene in a late infantile metachromatic
RT   leukodystrophy patient.";
RL   Clin. Genet. 52:65-67(1997).
RN   [36]
RP   VARIANTS MLD ASN-95; ARG-119; TYR-152; HIS-244; TYR-250; THR-314;
RP   ASN-367 AND CYS-384, AND VARIANT HIS-496.
RX   PubMed=9090526;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:3<234::AID-HUMU4>3.0.CO;2-7;
RA   Draghia R., Letourneur F., Drugan C., Manicom J., Blanchot C.,
RA   Kahn A., Poenaru L., Caillaud C.;
RT   "Metachromatic leukodystrophy: identification of the first deletion in
RT   exon 1 and of nine novel point mutations in the arylsulfatase A
RT   gene.";
RL   Hum. Mutat. 9:234-242(1997).
RN   [37]
RP   VARIANT MLD 406-SER--THR-408 DEL.
RX   PubMed=9490297; DOI=10.1007/s004390050652;
RA   Regis S., Filocamo M., Stroppiano M., Corsolini F., Caroli F.,
RA   Gatti R.;
RT   "A 9-bp deletion (2320del9) on the background of the arylsulfatase A
RT   pseudodeficiency allele in a metachromatic leukodystrophy patient and
RT   in a patient with nonprogressive neurological symptoms.";
RL   Hum. Genet. 102:50-53(1998).
RN   [38]
RP   VARIANTS MLD PRO-135 AND SER-179.
RX   PubMed=9600244; DOI=10.1007/s004390050721;
RA   Gomez-Lira M., Perusi C., Mottes M., Pignatti P.F., Manfredi M.,
RA   Rizzuto N., Salviati A.;
RT   "Molecular genetic characterization of two metachromatic
RT   leukodystrophy patients who carry the T799G mutation and show
RT   different phenotypes; description of a novel null-type mutation.";
RL   Hum. Genet. 102:459-463(1998).
RN   [39]
RP   ERRATUM.
RA   Gomez-Lira M., Perusi C., Mottes M., Pignatti P.F., Manfredi M.,
RA   Rizzuto N., Salviati A.;
RL   Hum. Genet. 102:602-602(1998).
RN   [40]
RP   VARIANT HIS-496.
RX   PubMed=9744473;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:4<238::AID-HUMU3>3.3.CO;2-N;
RA   Ricketts M.H., Poretz R.D., Manowitz P.;
RT   "The R496H mutation of arylsulfatase A does not cause metachromatic
RT   leukodystrophy.";
RL   Hum. Mutat. 12:238-239(1998).
RN   [41]
RP   VARIANTS MLD GLN-390 AND TYR-397.
RX   PubMed=9452102;
RA   Coulter-Mackie M.B., Gagnier L.;
RT   "Two novel mutations in the arylsulfatase A gene associated with
RT   juvenile (R390Q) and adult onset (H397Y) metachromatic
RT   leukodystrophy.";
RL   Hum. Mutat. Suppl. 1:S254-S256(1998).
RN   [42]
RP   VARIANT MLD SER-298, AND CHARACTERIZATION OF VARIANT MLD SER-298.
RX   PubMed=9819708; DOI=10.1023/A:1005405418215;
RA   Kurosawa K., Ida H., Eto Y.;
RT   "Prevalence of arylsulphatase A mutations in 11 Japanese patients with
RT   metachromatic leukodystrophy: identification of two novel mutations.";
RL   J. Inherit. Metab. Dis. 21:781-782(1998).
RN   [43]
RP   VARIANTS PRO-76; CYS-193; SER-391 AND VAL-464.
RX   PubMed=9888390;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:1<61::AID-HUMU7>3.0.CO;2-H;
RA   Berger J., Gmach M., Mayr U., Molzer B., Bernheimer H.;
RT   "Coincidence of two novel arylsulfatase A alleles and mutation
RT   459+1G>A within a family with metachromatic leukodystrophy: molecular
RT   basis of phenotypic heterogeneity.";
RL   Hum. Mutat. 13:61-68(1999).
RN   [44]
RP   VARIANTS MLD PHE-300 AND THR-425.
RX   PubMed=10220151;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:4<337::AID-HUMU14>3.0.CO;2-9;
RA   Marcao A., Amaral O., Pinto E., Pinto R., Sa Miranda M.C.;
RT   "Metachromatic leucodystrophy in Portugal-finding of four new
RT   molecular lesions: C300F, P425T, g.1190-1191insC, and g.2408delC.";
RL   Hum. Mutat. 13:337-338(1999).
RN   [45]
RP   VARIANTS MLD SER-32; PRO-68; TRP-84; ALA-94; VAL-99; SER-136; VAL-212;
RP   TYR-227; HIS-255; HIS-288; ASP-308; ILE-327 AND LEU-377, AND VARIANTS
RP   CYS-193; SER-350 AND SER-391.
RX   PubMed=10477432;
RX   DOI=10.1002/(SICI)1098-1004(1999)14:3<240::AID-HUMU7>3.0.CO;2-L;
RA   Gort L., Coll M.J., Chabas A.;
RT   "Identification of 12 novel mutations and two new polymorphisms in the
RT   arylsulfatase A gene: haplotype and genotype-phenotype correlation
RT   studies in Spanish metachromatic leukodystrophy patients.";
RL   Hum. Mutat. 14:240-248(1999).
RN   [46]
RP   VARIANTS MLD SER-179 AND TYR-281.
RX   PubMed=10533072;
RX   DOI=10.1002/(SICI)1098-1004(199911)14:5<447::AID-HUMU12>3.0.CO;2-1;
RA   Halsall D.J., Halligan E.P., Elsey T.S., Cox T.M.;
RT   "Metachromatic leucodystrophy: a newly identified mutation in
RT   arylsulphatase A, D281Y, found as a compound heterozygote with I179L
RT   in an adult onset case.";
RL   Hum. Mutat. 14:447-447(1999).
RN   [47]
RP   VARIANTS MLD LEU-148; THR-191; VAL-335; TYR-397 AND LEU-426.
RX   PubMed=10381328; DOI=10.1006/mgme.1999.2865;
RA   Qu Y., Shapira E., Desnick R.J.;
RT   "Metachromatic leukodystrophy: subtype genotype/phenotype correlations
RT   and identification of novel missense mutations (P148L and P191T)
RT   causing the juvenile-onset disease.";
RL   Mol. Genet. Metab. 67:206-212(1999).
RN   [48]
RP   VARIANTS MLD ASP-86; CYS-201; HIS-255 AND ASP-312, AND
RP   CHARACTERIZATION OF VARIANTS MLD ASP-86; CYS-201; HIS-255 AND ASP-312.
RX   PubMed=10751093;
RX   DOI=10.1002/(SICI)1096-8628(20000306)91:1<68::AID-AJMG13>3.0.CO;2-G;
RA   Hermann S., Schestag F., Polten A., Kafert S., Penzien J.,
RA   Zlotogora J., Baumann N., Gieselmann V.;
RT   "Characterization of four arylsulfatase A missense mutations G86D,
RT   Y201C, D255H, and E312D causing metachromatic leukodystrophy.";
RL   Am. J. Med. Genet. 91:68-73(2000).
RN   [49]
RP   VARIANT MLD PRO-286, AND VARIANT SER-391.
RX   PubMed=11061266; DOI=10.1212/WNL.55.7.1036;
RA   Felice K.J., Gomez Lira M., Natowicz M., Grunnet M.L., Tsongalis G.J.,
RA   Sima A.A.F., Kaplan R.F.;
RT   "Adult-onset MLD: a gene mutation with isolated polyneuropathy.";
RL   Neurology 55:1036-1039(2000).
RN   [50]
RP   VARIANT MLD GLY-143, AND CHARACTERIZATION OF VARIANT MLD GLY-143.
RX   PubMed=11020646; DOI=10.1016/S0887-8994(00)00164-8;
RA   Arbour L.T., Silver K., Hechtman P., Treacy E.P., Coulter-Mackie M.B.;
RT   "Variable onset of metachromatic leukodystrophy in a Vietnamese
RT   family.";
RL   Pediatr. Neurol. 23:173-176(2000).
RN   [51]
RP   VARIANT MLD ILE-408, AND VARIANTS CYS-193 AND SER-391.
RX   PubMed=11456299; DOI=10.1002/ana.1076;
RA   Comabella M., Waye J.S., Raguer N., Eng B., Dominguez C., Navarro C.,
RA   Borras C., Krivit W., Montalban X.;
RT   "Late-onset metachromatic leukodystrophy clinically presenting as
RT   isolated peripheral neuropathy: compound heterozygosity for the
RT   IVS2+1G-->A mutation and a newly identified missense mutation
RT   (Thr408Ile) in a Spanish family.";
RL   Ann. Neurol. 50:108-112(2001).
RN   [52]
RP   VARIANT MLD LYS-253, AND VARIANTS SER-350; SER-391 AND LEU-426.
RX   PubMed=11941485; DOI=10.1007/s00439-002-0701-y;
RA   Regis S., Corsolini F., Stroppiano M., Cusano R., Filocamo M.;
RT   "Contribution of arylsulfatase A mutations located on the same allele
RT   to enzyme activity reduction and metachromatic leukodystrophy
RT   severity.";
RL   Hum. Genet. 110:351-355(2002).
RN   [53]
RP   CHARACTERIZATION OF VARIANTS MLD PHE-300 AND THR-425.
RX   PubMed=12503099; DOI=10.1002/ajmg.a.10822;
RA   Marcao A., Simonis H., Schestag F., Sa Miranda M.C., Gieselmann V.;
RT   "Biochemical characterization of two (C300F, P425T) arylsulfatase A
RT   missense mutations.";
RL   Am. J. Med. Genet. A 116:238-242(2003).
RN   [54]
RP   CHARACTERIZATION OF VARIANTS MLD PHE-300 AND THR-425.
RX   PubMed=12788103; DOI=10.1016/S0006-291X(03)00969-0;
RA   Marcao A., Azevedo J.E., Gieselmann V., Sa Miranda M.C.;
RT   "Oligomerization capacity of two arylsulfatase A mutants: C300F and
RT   P425T.";
RL   Biochem. Biophys. Res. Commun. 306:293-297(2003).
RN   [55]
RP   VARIANTS MLD LEU-155; GLN-181; VAL-212; HIS-306; SER-325; VAL-335;
RP   LEU-426 AND SER-429.
RX   PubMed=14517960; DOI=10.1002/humu.9190;
RA   Eng B., Nakamura L.N., O'Reilly N., Schokman N., Nowaczyk M.M.J.,
RA   Krivit W., Waye J.S.;
RT   "Identification of nine novel arylsulfatase A (ARSA) gene mutations in
RT   patients with metachromatic leukodystrophy (MLD).";
RL   Hum. Mutat. 22:418-419(2003).
RN   [56]
RP   VARIANTS MLD SER-136; SER-247; GLU-381 LEU-426 AND GLY-469.
RX   PubMed=14680985; DOI=10.1016/j.ymgme.2003.08.004;
RA   Olkhovich N.V., Takamura N., Pichkur N.A., Gorovenko N.G., Aoyagi K.,
RA   Yamashita S.;
RT   "Novel mutations in arylsulfatase A gene in three Ukrainian families
RT   with metachromatic leukodystrophy.";
RL   Mol. Genet. Metab. 80:360-363(2003).
RN   [57]
RP   VARIANTS MLD ASN-29; ARG-156; SER-179; SER-293; TYR-294; SER-309 AND
RP   LEU-426, VARIANTS CYS-193 AND SER-391, AND CHARACTERIZATION OF
RP   VARIANTS MLD ASN-29; ARG-156; SER-293 AND TYR-294.
RX   PubMed=15326627; DOI=10.1002/ajmg.a.30118;
RA   Berna L., Gieselmann V., Poupetova H., Hrebicek M., Elleder M.,
RA   Ledvinova J.;
RT   "Novel mutations associated with metachromatic leukodystrophy:
RT   phenotype and expression studies in nine Czech and Slovak patients.";
RL   Am. J. Med. Genet. A 129:277-281(2004).
RN   [58]
RP   VARIANTS MLD ASP-293 AND GLY-489, AND VARIANT SER-350.
RX   PubMed=15026521; DOI=10.1136/jnnp.2003.017400;
RA   Gallo S., Randi D., Bertelli M., Salviati A., Pandolfo M.;
RT   "Late onset MLD with normal nerve conduction associated with two novel
RT   missense mutations in the ASA gene.";
RL   J. Neurol. Neurosurg. Psych. 75:655-657(2004).
RN   [59]
RP   VARIANT MLD VAL-219, AND CHARACTERIZATION OF VARIANT MLD VAL-219.
RX   PubMed=15710861; DOI=10.1001/archneur.62.2.309;
RA   Marcao A.M., Wiest R., Schindler K., Wiesmann U., Weis J., Schroth G.,
RA   Miranda M.C.S., Sturzenegger M., Gieselmann V.;
RT   "Adult onset metachromatic leukodystrophy without electroclinical
RT   peripheral nervous system involvement: a new mutation in the ARSA
RT   gene.";
RL   Arch. Neurol. 62:309-313(2005).
RN   [60]
RP   VARIANTS MLD ASP-18; HIS-30; GLN-84; PRO-137 DEL; ASP-154; SER-179;
RP   CYS-201; PRO-212; HIS-217; LYS-253; SER-282; ASN-302; TRP-370;
RP   ASN-376; TRP-390 AND PRO-428, AND CHARACTERIZATION OF VARIANTS MLD
RP   ASP-18; HIS-30; PRO-212; HIS-217; SER-282; ASN-302; TRP-370 AND
RP   ASN-376.
RX   PubMed=18693274; DOI=10.1002/humu.20851;
RA   Grossi S., Regis S., Rosano C., Corsolini F., Uziel G., Sessa M.,
RA   Di Rocco M., Parenti G., Deodato F., Leuzzi V., Biancheri R.,
RA   Filocamo M.;
RT   "Molecular analysis of ARSA and PSAP genes in twenty-one Italian
RT   patients with metachromatic leukodystrophy: identification and
RT   functional characterization of 11 novel ARSA alleles.";
RL   Hum. Mutat. 29:E220-E230(2008).
RN   [61]
RP   VARIANTS MLD PRO-52; ASP-138; PRO-212; MET-304; LYS-307 AND GLY-406,
RP   AND CHARACTERIZATION OF VARIANTS MLD PRO-52; ASP-138; PRO-212;
RP   MET-304; LYS-307 AND GLY-406.
RX   PubMed=19606494; DOI=10.1002/humu.21093;
RA   Cesani M., Capotondo A., Plati T., Sergi L.S., Fumagalli F.,
RA   Roncarolo M.G., Naldini L., Comi G., Sessa M., Biffi A.;
RT   "Characterization of new arylsulfatase A gene mutations reinforces
RT   genotype-phenotype correlation in metachromatic leukodystrophy.";
RL   Hum. Mutat. 30:E936-E945(2009).
RN   [62]
RP   VARIANTS MLD SER-179; SER-247; CYS-288; VAL-335; LYS-382; GLN-390;
RP   TRP-390; TYR-397 AND LEU-426.
RX   PubMed=20339381; DOI=10.1038/jhg.2010.25;
RA   Lugowska A., Ploski R., Wlodarski P., Tylki-Szymanska A.;
RT   "Molecular bases of metachromatic leukodystrophy in Polish patients.";
RL   J. Hum. Genet. 55:394-396(2010).
RN   [63]
RP   VARIANTS MLD ASP-99 AND ILE-409.
RX   PubMed=21265945; DOI=10.1111/j.1440-1819.2010.02169.x;
RA   Hayashi T., Nakamura M., Ichiba M., Matsuda M., Kato M., Shiokawa N.,
RA   Shimo H., Tomiyasu A., Mori S., Tomiyasu Y., Ishizuka T., Inamori Y.,
RA   Okamoto Y., Umehara F., Arimura K., Nakabeppu Y., Sano A.;
RT   "Adult-type metachromatic leukodystrophy with compound heterozygous
RT   ARSA mutations: a case report and phenotypic comparison with a
RT   previously reported case.";
RL   Psychiatry Clin. Neurosci. 65:105-108(2011).
CC   -!- FUNCTION: Hydrolyzes cerebroside sulfate.
CC   -!- CATALYTIC ACTIVITY: A cerebroside 3-sulfate + H(2)O = a
CC       cerebroside + sulfate.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000269|PubMed:12888274};
CC       Note=Binds 1 Ca(2+) ion per subunit.
CC       {ECO:0000269|PubMed:12888274};
CC   -!- ENZYME REGULATION: Inhibited by phosphate. The phosphate forms a
CC       covalent bond with the active site 3-oxoalanine.
CC       {ECO:0000269|PubMed:12888274}.
CC   -!- SUBUNIT: Homodimer at neutral pH and homooctamer at acidic pH.
CC       Exists both as a single chain of 58 kDa (component A) or as a
CC       chain of 50 kDa (component B) linked by disulfide bond(s) to a 7
CC       kDa chain (component C). Interacts with SUMF1.
CC       {ECO:0000269|PubMed:12888274, ECO:0000269|PubMed:1352993,
CC       ECO:0000269|PubMed:16368756}.
CC   -!- INTERACTION:
CC       Q15645:TRIP13; NbExp=9; IntAct=EBI-2117357, EBI-358993;
CC   -!- SUBCELLULAR LOCATION: Lysosome.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P15289-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P15289-2; Sequence=VSP_046190;
CC         Note=No experimental confirmation available.;
CC   -!- PTM: The conversion to 3-oxoalanine (also known as C-
CC       formylglycine, FGly), of a serine or cysteine residue in
CC       prokaryotes and of a cysteine residue in eukaryotes, is critical
CC       for catalytic activity. This post-translational modification is
CC       severely defective in multiple sulfatase deficiency (MSD).
CC       {ECO:0000269|PubMed:7628016}.
CC   -!- DISEASE: Leukodystrophy metachromatic (MLD) [MIM:250100]: A
CC       leukodystrophy due to a lysosomal storage defect. Characterized by
CC       intralysosomal storage of cerebroside-3-sulfate in neural and non-
CC       neural tissues, with a diffuse loss of myelin in the central
CC       nervous system. Progressive demyelination causes a variety of
CC       neurological symptoms, including gait disturbances, ataxias,
CC       optical atrophy, dementia, seizures, and spastic tetraparesis.
CC       Three forms of the disease can be distinguished according to the
CC       age at onset: late-infantile, juvenile and adult.
CC       {ECO:0000269|PubMed:10220151, ECO:0000269|PubMed:10381328,
CC       ECO:0000269|PubMed:10477432, ECO:0000269|PubMed:10533072,
CC       ECO:0000269|PubMed:10751093, ECO:0000269|PubMed:11020646,
CC       ECO:0000269|PubMed:11061266, ECO:0000269|PubMed:11456299,
CC       ECO:0000269|PubMed:11941485, ECO:0000269|PubMed:12503099,
CC       ECO:0000269|PubMed:12788103, ECO:0000269|PubMed:1353340,
CC       ECO:0000269|PubMed:14517960, ECO:0000269|PubMed:14680985,
CC       ECO:0000269|PubMed:15026521, ECO:0000269|PubMed:15326627,
CC       ECO:0000269|PubMed:15710861, ECO:0000269|PubMed:1670590,
CC       ECO:0000269|PubMed:1673291, ECO:0000269|PubMed:1678251,
CC       ECO:0000269|PubMed:18693274, ECO:0000269|PubMed:19606494,
CC       ECO:0000269|PubMed:20339381, ECO:0000269|PubMed:21265945,
CC       ECO:0000269|PubMed:7581401, ECO:0000269|PubMed:7825603,
CC       ECO:0000269|PubMed:7860068, ECO:0000269|PubMed:7902317,
CC       ECO:0000269|PubMed:7906588, ECO:0000269|PubMed:7909527,
CC       ECO:0000269|PubMed:8095918, ECO:0000269|PubMed:8101038,
CC       ECO:0000269|PubMed:8101083, ECO:0000269|PubMed:8104633,
CC       ECO:0000269|PubMed:8891236, ECO:0000269|PubMed:9090526,
CC       ECO:0000269|PubMed:9272717, ECO:0000269|PubMed:9452102,
CC       ECO:0000269|PubMed:9490297, ECO:0000269|PubMed:9600244,
CC       ECO:0000269|PubMed:9819708}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Multiple sulfatase deficiency (MSD) [MIM:272200]: A
CC       clinically and biochemically heterogeneous disorder caused by the
CC       simultaneous impairment of all sulfatases, due to defective post-
CC       translational modification and activation. It combines features of
CC       individual sulfatase deficiencies such as metachromatic
CC       leukodystrophy, mucopolysaccharidosis, chondrodysplasia punctata,
CC       hydrocephalus, ichthyosis, neurologic deterioration and
CC       developmental delay. {ECO:0000269|PubMed:15146462}. Note=The
CC       protein represented in this entry is involved in disease
CC       pathogenesis. Arylsulfatase A activity is impaired in multiple
CC       sulfatase deficiency due to mutations in SUMF1 (PubMed:15146462).
CC       SUMF1 mutations result in defective post-translational
CC       modification of ARSA at residue Cys-69 that is not converted to 3-
CC       oxoalanine (PubMed:7628016). {ECO:0000269|PubMed:15146462,
CC       ECO:0000269|PubMed:7628016}.
CC   -!- MISCELLANEOUS: The metal cofactor was first identified as
CC       magnesium ion, based on the structure of the recombinant protein,
CC       but when purified from human placenta, the protein contains 1
CC       calcium ion per subunit.
CC   -!- SIMILARITY: Belongs to the sulfatase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB03341.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAH11167.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/arsa/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Arylsulfatase A entry;
CC       URL="https://en.wikipedia.org/wiki/Arylsulfatase_A";
CC   -!- WEB RESOURCE: Name=Arylsulfatase A (ARSA); Note=Leiden Open
CC       Variation Database (LOVD);
CC       URL="http://grenada.lumc.nl/LOVD2/mendelian_genes/home.php?select_db=ARSA";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X52151; CAA36399.1; -; mRNA.
DR   EMBL; X52150; CAA36398.1; -; Genomic_DNA.
DR   EMBL; AB448736; BAH11167.1; ALT_INIT; mRNA.
DR   EMBL; CR456383; CAG30269.1; -; mRNA.
DR   EMBL; AK098659; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK315011; BAG37503.1; -; mRNA.
DR   EMBL; AY271820; AAP03431.1; -; Genomic_DNA.
DR   EMBL; U62317; AAB03341.1; ALT_INIT; Genomic_DNA.
DR   EMBL; BC014210; AAH14210.2; -; mRNA.
DR   CCDS; CCDS46736.1; -. [P15289-2]
DR   PIR; S11031; KJHUAA.
DR   RefSeq; NP_000478.3; NM_000487.5.
DR   RefSeq; NP_001078894.2; NM_001085425.2.
DR   RefSeq; NP_001078895.2; NM_001085426.2.
DR   RefSeq; NP_001078896.2; NM_001085427.2.
DR   RefSeq; NP_001078897.1; NM_001085428.2. [P15289-2]
DR   RefSeq; XP_011528992.1; XM_011530690.2. [P15289-2]
DR   UniGene; Hs.731715; -.
DR   UniGene; Hs.88251; -.
DR   PDB; 1AUK; X-ray; 2.10 A; A=19-507.
DR   PDB; 1E1Z; X-ray; 2.40 A; P=19-507.
DR   PDB; 1E2S; X-ray; 2.35 A; P=19-507.
DR   PDB; 1E33; X-ray; 2.50 A; P=19-507.
DR   PDB; 1E3C; X-ray; 2.65 A; P=19-507.
DR   PDB; 1N2K; X-ray; 2.75 A; A=19-507.
DR   PDB; 1N2L; X-ray; 3.20 A; A=19-507.
DR   PDB; 2AIJ; X-ray; 1.55 A; P=69-73.
DR   PDB; 2AIK; X-ray; 1.73 A; P=68-74.
DR   PDB; 2HI8; X-ray; 1.64 A; P=69-73.
DR   PDBsum; 1AUK; -.
DR   PDBsum; 1E1Z; -.
DR   PDBsum; 1E2S; -.
DR   PDBsum; 1E33; -.
DR   PDBsum; 1E3C; -.
DR   PDBsum; 1N2K; -.
DR   PDBsum; 1N2L; -.
DR   PDBsum; 2AIJ; -.
DR   PDBsum; 2AIK; -.
DR   PDBsum; 2HI8; -.
DR   ProteinModelPortal; P15289; -.
DR   SMR; P15289; -.
DR   BioGrid; 106903; 21.
DR   IntAct; P15289; 17.
DR   STRING; 9606.ENSP00000216124; -.
DR   ChEMBL; CHEMBL2193; -.
DR   DrugBank; DB03821; 2-Amino-3-Hydroxy-3-Phosphonooxy-Propionic Acid.
DR   DrugBank; DB01141; Micafungin.
DR   DrugBank; DB04786; Suramin.
DR   SwissLipids; SLP:000000913; -.
DR   UniCarbKB; P15289; -.
DR   BioMuta; ARSA; -.
DR   EPD; P15289; -.
DR   MaxQB; P15289; -.
DR   PaxDb; P15289; -.
DR   PeptideAtlas; P15289; -.
DR   PRIDE; P15289; -.
DR   DNASU; 410; -.
DR   Ensembl; ENST00000453344; ENSP00000412542; ENSG00000100299. [P15289-2]
DR   GeneID; 410; -.
DR   KEGG; hsa:410; -.
DR   UCSC; uc003bmz.6; human. [P15289-1]
DR   CTD; 410; -.
DR   DisGeNET; 410; -.
DR   GeneCards; ARSA; -.
DR   GeneReviews; ARSA; -.
DR   HGNC; HGNC:713; ARSA.
DR   HPA; CAB025183; -.
DR   HPA; HPA005554; -.
DR   MalaCards; ARSA; -.
DR   MIM; 250100; phenotype.
DR   MIM; 272200; phenotype.
DR   MIM; 607574; gene.
DR   neXtProt; NX_P15289; -.
DR   OpenTargets; ENSG00000100299; -.
DR   Orphanet; 309271; Metachromatic leukodystrophy, adult form.
DR   Orphanet; 309263; Metachromatic leukodystrophy, juvenile form.
DR   Orphanet; 309256; Metachromatic leukodystrophy, late infantile form.
DR   Orphanet; 751; Pseudoarylsulfatase A deficiency.
DR   PharmGKB; PA25005; -.
DR   eggNOG; KOG3867; Eukaryota.
DR   eggNOG; COG3119; LUCA.
DR   GeneTree; ENSGT00760000119062; -.
DR   HOGENOM; HOG000135352; -.
DR   HOVERGEN; HBG004283; -.
DR   InParanoid; P15289; -.
DR   KO; K01134; -.
DR   PhylomeDB; P15289; -.
DR   Reactome; R-HSA-1660662; Glycosphingolipid metabolism.
DR   Reactome; R-HSA-1663150; The activation of arylsulfatases.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SABIO-RK; P15289; -.
DR   SIGNOR; P15289; -.
DR   ChiTaRS; ARSA; human.
DR   EvolutionaryTrace; P15289; -.
DR   GeneWiki; Arylsulfatase_A; -.
DR   GenomeRNAi; 410; -.
DR   PMAP-CutDB; P15289; -.
DR   PRO; PR:P15289; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   Bgee; ENSG00000100299; -.
DR   CleanEx; HS_ARSA; -.
DR   ExpressionAtlas; P15289; baseline and differential.
DR   Genevisible; P15289; HS.
DR   GO; GO:0035578; C:azurophil granule lumen; TAS:Reactome.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005764; C:lysosome; TAS:ProtInc.
DR   GO; GO:0004065; F:arylsulfatase activity; TAS:ProtInc.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0004098; F:cerebroside-sulfatase activity; TAS:Reactome.
DR   GO; GO:0008484; F:sulfuric ester hydrolase activity; IDA:MGI.
DR   GO; GO:0006687; P:glycosphingolipid metabolic process; TAS:Reactome.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   Gene3D; 3.40.720.10; -; 1.
DR   InterPro; IPR017849; Alkaline_Pase-like_a/b/a.
DR   InterPro; IPR017850; Alkaline_phosphatase_core.
DR   InterPro; IPR024607; Sulfatase_CS.
DR   InterPro; IPR000917; Sulfatase_N.
DR   Pfam; PF00884; Sulfatase; 1.
DR   SUPFAM; SSF53649; SSF53649; 1.
DR   PROSITE; PS00523; SULFATASE_1; 1.
DR   PROSITE; PS00149; SULFATASE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Glycoprotein; Hydrolase; Ichthyosis; Leukodystrophy; Lysosome;
KW   Metachromatic leukodystrophy; Metal-binding; Polymorphism;
KW   Reference proteome; Signal.
FT   SIGNAL        1     18       {ECO:0000269|PubMed:1352993}.
FT   CHAIN        19    507       Arylsulfatase A.
FT                                /FTId=PRO_0000033417.
FT   CHAIN        19    444       Arylsulfatase A component B.
FT                                /FTId=PRO_0000033418.
FT   CHAIN       448    507       Arylsulfatase A component C.
FT                                /FTId=PRO_0000033419.
FT   ACT_SITE    125    125       {ECO:0000269|PubMed:12888274}.
FT   METAL        29     29       Calcium.
FT   METAL        30     30       Calcium.
FT   METAL        69     69       Calcium; via 3-oxoalanine.
FT   METAL       281    281       Calcium.
FT   METAL       282    282       Calcium.
FT   BINDING     123    123       Substrate.
FT   BINDING     150    150       Substrate.
FT   BINDING     229    229       Substrate.
FT   BINDING     302    302       Substrate.
FT   MOD_RES      69     69       3-oxoalanine (Cys).
FT                                {ECO:0000269|PubMed:7628016}.
FT   CARBOHYD    158    158       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:12888274,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    184    184       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:12888274}.
FT   CARBOHYD    350    350       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   DISULFID    156    172
FT   DISULFID    161    168
FT   DISULFID    300    414
FT   DISULFID    488    500
FT   DISULFID    489    502
FT   DISULFID    493    499
FT   VAR_SEQ       1     84       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_046190.
FT   VARIANT      18     18       A -> D (in MLD; enzyme activity reduced
FT                                to 5% of wild-type enzyme;
FT                                dbSNP:rs199476339).
FT                                {ECO:0000269|PubMed:18693274}.
FT                                /FTId=VAR_054164.
FT   VARIANT      29     29       D -> N (in MLD; infantile-onset; causes a
FT                                severe reduction of enzyme activity;
FT                                dbSNP:rs199476346).
FT                                {ECO:0000269|PubMed:15326627}.
FT                                /FTId=VAR_054165.
FT   VARIANT      30     30       D -> H (in MLD; enzyme activity reduced
FT                                to 2.4% of wild-type enzyme;
FT                                dbSNP:rs199476340).
FT                                {ECO:0000269|PubMed:18693274}.
FT                                /FTId=VAR_054166.
FT   VARIANT      32     32       G -> S (in MLD; late-infantile form;
FT                                dbSNP:rs199476350).
FT                                {ECO:0000269|PubMed:10477432}.
FT                                /FTId=VAR_054167.
FT   VARIANT      52     52       L -> P (in MLD; loss of enzymatic
FT                                activity; dbSNP:rs199476357).
FT                                {ECO:0000269|PubMed:19606494}.
FT                                /FTId=VAR_067414.
FT   VARIANT      68     68       L -> P (in MLD; late-infantile form;
FT                                dbSNP:rs199476351).
FT                                {ECO:0000269|PubMed:10477432}.
FT                                /FTId=VAR_054168.
FT   VARIANT      76     76       L -> P (in dbSNP:rs199476362).
FT                                {ECO:0000269|PubMed:9888390}.
FT                                /FTId=VAR_007243.
FT   VARIANT      82     82       P -> L (in MLD; late-infantile-onset;
FT                                dbSNP:rs6151411).
FT                                {ECO:0000269|PubMed:7581401,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_007244.
FT   VARIANT      84     84       R -> Q (in MLD; mild; dbSNP:rs74315458).
FT                                {ECO:0000269|PubMed:1353340,
FT                                ECO:0000269|PubMed:18693274}.
FT                                /FTId=VAR_007245.
FT   VARIANT      84     84       R -> W (in MLD; juvenile form;
FT                                dbSNP:rs199476352).
FT                                {ECO:0000269|PubMed:10477432}.
FT                                /FTId=VAR_054169.
FT   VARIANT      86     86       G -> D (in MLD; severe; no enzyme
FT                                residual activity; leads to a decreased
FT                                stability of the mutant enzyme; causes an
FT                                arrest of the mutant enzyme polypeptide
FT                                in a prelysosomal compartment;
FT                                dbSNP:rs74315460).
FT                                {ECO:0000269|PubMed:10751093,
FT                                ECO:0000269|PubMed:7825603}.
FT                                /FTId=VAR_007246.
FT   VARIANT      94     94       P -> A (in MLD; adult form;
FT                                dbSNP:rs199476353).
FT                                {ECO:0000269|PubMed:10477432}.
FT                                /FTId=VAR_054170.
FT   VARIANT      95     95       S -> N (in MLD; dbSNP:rs199476363).
FT                                {ECO:0000269|PubMed:9090526}.
FT                                /FTId=VAR_007247.
FT   VARIANT      96     96       S -> F (in MLD; severe;
FT                                dbSNP:rs74315456).
FT                                {ECO:0000269|PubMed:1678251}.
FT                                /FTId=VAR_007248.
FT   VARIANT      96     96       S -> L (in MLD; severe; no enzyme
FT                                residual activity; dbSNP:rs199476371).
FT                                {ECO:0000269|PubMed:7825603}.
FT                                /FTId=VAR_007249.
FT   VARIANT      99     99       G -> D (in MLD; adult type;
FT                                dbSNP:rs74315455).
FT                                {ECO:0000269|PubMed:1673291,
FT                                ECO:0000269|PubMed:21265945}.
FT                                /FTId=VAR_007250.
FT   VARIANT      99     99       G -> V (in MLD; late-infantile form;
FT                                dbSNP:rs74315455).
FT                                {ECO:0000269|PubMed:10477432}.
FT                                /FTId=VAR_054171.
FT   VARIANT     119    119       G -> R (in MLD; juvenile-onset;
FT                                dbSNP:rs199476364).
FT                                {ECO:0000269|PubMed:9090526}.
FT                                /FTId=VAR_007251.
FT   VARIANT     122    122       G -> S (in MLD; adult type;
FT                                dbSNP:rs74315461).
FT                                {ECO:0000269|PubMed:7902317}.
FT                                /FTId=VAR_007252.
FT   VARIANT     135    135       L -> P (in MLD; dbSNP:rs121434215).
FT                                {ECO:0000269|PubMed:9600244}.
FT                                /FTId=VAR_007253.
FT   VARIANT     136    136       P -> L (in MLD; severe late-infantile
FT                                type; loss of enzymatic activity;
FT                                dbSNP:rs74315462).
FT                                {ECO:0000269|PubMed:7860068}.
FT                                /FTId=VAR_007254.
FT   VARIANT     136    136       P -> S (in MLD; late-infantile form;
FT                                dbSNP:rs60504011).
FT                                {ECO:0000269|PubMed:10477432,
FT                                ECO:0000269|PubMed:14680985}.
FT                                /FTId=VAR_054172.
FT   VARIANT     137    137       Missing (in MLD).
FT                                {ECO:0000269|PubMed:18693274}.
FT                                /FTId=VAR_054173.
FT   VARIANT     138    138       H -> D (in MLD; significantly lower
FT                                activity than wild-type protein;
FT                                dbSNP:rs199476358).
FT                                {ECO:0000269|PubMed:19606494}.
FT                                /FTId=VAR_067415.
FT   VARIANT     143    143       R -> G (in MLD; juvenile/adult-onset;
FT                                generates 5% as much activity as the
FT                                parallel normal control;
FT                                dbSNP:rs199476373).
FT                                {ECO:0000269|PubMed:11020646}.
FT                                /FTId=VAR_054174.
FT   VARIANT     148    148       P -> L (in MLD; juvenile-onset;
FT                                dbSNP:rs199476375).
FT                                {ECO:0000269|PubMed:10381328}.
FT                                /FTId=VAR_054175.
FT   VARIANT     152    152       D -> Y (in MLD; dbSNP:rs199476365).
FT                                {ECO:0000269|PubMed:9090526}.
FT                                /FTId=VAR_007255.
FT   VARIANT     153    153       Q -> H (in MLD; late-infantile form; no
FT                                enzyme residual activity;
FT                                dbSNP:rs199476377).
FT                                {ECO:0000269|PubMed:8891236}.
FT                                /FTId=VAR_054176.
FT   VARIANT     154    154       G -> D (in MLD; dbSNP:rs74315463).
FT                                {ECO:0000269|PubMed:18693274}.
FT                                /FTId=VAR_007256.
FT   VARIANT     155    155       P -> L (in MLD; juvenile-onset;
FT                                dbSNP:rs74315464).
FT                                {ECO:0000269|PubMed:14517960}.
FT                                /FTId=VAR_054177.
FT   VARIANT     155    155       P -> R (in MLD; dbSNP:rs74315464).
FT                                /FTId=VAR_007257.
FT   VARIANT     156    156       C -> R (in MLD; adult type; enzyme
FT                                activity reduced to 50% of wild-type
FT                                enzyme; dbSNP:rs199476348).
FT                                {ECO:0000269|PubMed:15326627}.
FT                                /FTId=VAR_054178.
FT   VARIANT     167    167       P -> R (in MLD; dbSNP:rs74315465).
FT                                /FTId=VAR_007258.
FT   VARIANT     169    169       D -> N (in MLD; dbSNP:rs74315466).
FT                                /FTId=VAR_007259.
FT   VARIANT     172    172       C -> Y (in MLD; juvenile-onset;
FT                                dbSNP:rs199476381).
FT                                {ECO:0000269|PubMed:7581401}.
FT                                /FTId=VAR_007260.
FT   VARIANT     179    179       I -> S (in MLD; mild; dbSNP:rs74315457).
FT                                {ECO:0000269|PubMed:10533072,
FT                                ECO:0000269|PubMed:15326627,
FT                                ECO:0000269|PubMed:18693274,
FT                                ECO:0000269|PubMed:20339381,
FT                                ECO:0000269|PubMed:9600244}.
FT                                /FTId=VAR_007261.
FT   VARIANT     181    181       L -> Q (in MLD; infantile form;
FT                                dbSNP:rs199476378).
FT                                {ECO:0000269|PubMed:14517960}.
FT                                /FTId=VAR_054179.
FT   VARIANT     190    190       Q -> H (in MLD; no enzyme residual
FT                                activity; dbSNP:rs199476372).
FT                                {ECO:0000269|PubMed:7825603}.
FT                                /FTId=VAR_054180.
FT   VARIANT     191    191       P -> T (in MLD; juvenile-onset;
FT                                dbSNP:rs199476374).
FT                                {ECO:0000269|PubMed:10381328}.
FT                                /FTId=VAR_054181.
FT   VARIANT     193    193       W -> C (in dbSNP:rs6151415).
FT                                {ECO:0000269|PubMed:10477432,
FT                                ECO:0000269|PubMed:11456299,
FT                                ECO:0000269|PubMed:15326627,
FT                                ECO:0000269|PubMed:1670590,
FT                                ECO:0000269|PubMed:9888390,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_007262.
FT   VARIANT     201    201       Y -> C (in MLD; juvenile-onset; results
FT                                in higly reduced enzyme activity and
FT                                stability; the mutant enzyme is kept in a
FT                                prelysosomal compartment;
FT                                dbSNP:rs199476345).
FT                                {ECO:0000269|PubMed:10751093,
FT                                ECO:0000269|PubMed:18693274,
FT                                ECO:0000269|PubMed:7581401}.
FT                                /FTId=VAR_007263.
FT   VARIANT     212    212       A -> P (in MLD; loss of enzymatic
FT                                activity; dbSNP:rs199476341).
FT                                {ECO:0000269|PubMed:18693274,
FT                                ECO:0000269|PubMed:19606494}.
FT                                /FTId=VAR_054182.
FT   VARIANT     212    212       A -> V (in MLD; dbSNP:rs74315467).
FT                                {ECO:0000269|PubMed:10477432,
FT                                ECO:0000269|PubMed:14517960,
FT                                ECO:0000269|PubMed:7906588}.
FT                                /FTId=VAR_007264.
FT   VARIANT     217    217       R -> H (in MLD; enzyme activity reduced
FT                                to 15.6% of wild-type enzyme;
FT                                dbSNP:rs148403406).
FT                                {ECO:0000269|PubMed:18693274}.
FT                                /FTId=VAR_054183.
FT   VARIANT     219    219       F -> V (in MLD; enzyme activity reduced
FT                                to less than 1% of normal activity;
FT                                dbSNP:rs199476383).
FT                                {ECO:0000269|PubMed:15710861}.
FT                                /FTId=VAR_054184.
FT   VARIANT     224    224       A -> V (in MLD; dbSNP:rs74315468).
FT                                {ECO:0000269|PubMed:7906588}.
FT                                /FTId=VAR_007265.
FT   VARIANT     227    227       H -> Y (in MLD; late-infantile form;
FT                                dbSNP:rs199476354).
FT                                {ECO:0000269|PubMed:10477432}.
FT                                /FTId=VAR_054185.
FT   VARIANT     231    231       P -> T (in MLD; dbSNP:rs74315469).
FT                                /FTId=VAR_007266.
FT   VARIANT     244    244       R -> C (in MLD; juvenile-onset;
FT                                dbSNP:rs74315470).
FT                                /FTId=VAR_007267.
FT   VARIANT     244    244       R -> H (in MLD; infantile-onset;
FT                                dbSNP:rs199476366).
FT                                {ECO:0000269|PubMed:9090526}.
FT                                /FTId=VAR_007268.
FT   VARIANT     245    245       G -> R (in MLD; severe;
FT                                dbSNP:rs74315471).
FT                                {ECO:0000269|PubMed:8101083}.
FT                                /FTId=VAR_007269.
FT   VARIANT     247    247       F -> S (in MLD; dbSNP:rs199476384).
FT                                {ECO:0000269|PubMed:14680985,
FT                                ECO:0000269|PubMed:20339381}.
FT                                /FTId=VAR_054186.
FT   VARIANT     250    250       S -> Y (in MLD; infantile-onset;
FT                                dbSNP:rs199476367).
FT                                {ECO:0000269|PubMed:9090526}.
FT                                /FTId=VAR_007270.
FT   VARIANT     253    253       E -> K (in MLD; late-infantile;
FT                                dbSNP:rs74315483).
FT                                {ECO:0000269|PubMed:11941485,
FT                                ECO:0000269|PubMed:18693274}.
FT                                /FTId=VAR_054187.
FT   VARIANT     255    255       D -> H (in MLD; late-infantile form; no
FT                                enzyme residual activity; leads to a
FT                                decreased stability of the mutant enzyme;
FT                                causes an arrest of the mutant enzyme
FT                                polypeptide in a prelysosomal
FT                                compartment; dbSNP:rs80338819).
FT                                {ECO:0000269|PubMed:10477432,
FT                                ECO:0000269|PubMed:10751093}.
FT                                /FTId=VAR_054188.
FT   VARIANT     274    274       T -> M (in MLD; severe; 35% of normal
FT                                activity; dbSNP:rs74315472).
FT                                {ECO:0000269|PubMed:7825603,
FT                                ECO:0000269|PubMed:8104633,
FT                                ECO:0000269|PubMed:8723680}.
FT                                /FTId=VAR_007271.
FT   VARIANT     281    281       D -> Y (in MLD; dbSNP:rs199476386).
FT                                {ECO:0000269|PubMed:10533072}.
FT                                /FTId=VAR_054189.
FT   VARIANT     282    282       N -> S (in MLD; enzyme activity reduced
FT                                to 0.6% of wild-type enzyme;
FT                                dbSNP:rs199476342).
FT                                {ECO:0000269|PubMed:18693274}.
FT                                /FTId=VAR_054190.
FT   VARIANT     286    286       T -> P (in MLD; adult type;
FT                                dbSNP:rs28940894).
FT                                {ECO:0000269|PubMed:11061266}.
FT                                /FTId=VAR_054191.
FT   VARIANT     288    288       R -> C (in MLD; dbSNP:rs74315473).
FT                                {ECO:0000269|PubMed:20339381}.
FT                                /FTId=VAR_007272.
FT   VARIANT     288    288       R -> H (in MLD; adult form;
FT                                dbSNP:rs199476355).
FT                                {ECO:0000269|PubMed:10477432}.
FT                                /FTId=VAR_054192.
FT   VARIANT     293    293       G -> D (in MLD; late-onset;
FT                                dbSNP:rs199476387).
FT                                {ECO:0000269|PubMed:15026521}.
FT                                /FTId=VAR_054193.
FT   VARIANT     293    293       G -> S (in MLD; adult type; causes a
FT                                severe reduction of enzyme activity;
FT                                dbSNP:rs199476349).
FT                                {ECO:0000269|PubMed:15326627}.
FT                                /FTId=VAR_054194.
FT   VARIANT     294    294       C -> Y (in MLD; juvenile-onset; causes a
FT                                severe reduction of enzyme activity;
FT                                dbSNP:rs199476347).
FT                                {ECO:0000269|PubMed:15326627}.
FT                                /FTId=VAR_054195.
FT   VARIANT     295    295       S -> Y (in MLD; severe;
FT                                dbSNP:rs74315474).
FT                                {ECO:0000269|PubMed:7906588}.
FT                                /FTId=VAR_007273.
FT   VARIANT     298    298       L -> S (in MLD; late-infantile form;
FT                                complete loss of enzyme activity;
FT                                dbSNP:rs199476389).
FT                                {ECO:0000269|PubMed:9819708}.
FT                                /FTId=VAR_054196.
FT   VARIANT     300    300       C -> F (in MLD; late-infantile-onset;
FT                                enzyme activity reduced to less than 1%;
FT                                the mutant protein is more rapidly
FT                                degraded in lysosomes; strongly
FT                                interferes with the octamerization
FT                                process of the enzyme at low pH;
FT                                dbSNP:rs74315484).
FT                                {ECO:0000269|PubMed:10220151,
FT                                ECO:0000269|PubMed:12503099,
FT                                ECO:0000269|PubMed:12788103}.
FT                                /FTId=VAR_008132.
FT   VARIANT     302    302       K -> N (in MLD; enzyme activity reduced
FT                                to 2.8% of wild-type enzyme;
FT                                dbSNP:rs199476343).
FT                                {ECO:0000269|PubMed:18693274}.
FT                                /FTId=VAR_054197.
FT   VARIANT     304    304       T -> M (in MLD; loss of enzymatic
FT                                activity; dbSNP:rs199476359).
FT                                {ECO:0000269|PubMed:19606494}.
FT                                /FTId=VAR_067416.
FT   VARIANT     306    306       Y -> H (in MLD; juvenile-onset;
FT                                dbSNP:rs199476379).
FT                                {ECO:0000269|PubMed:14517960}.
FT                                /FTId=VAR_054198.
FT   VARIANT     307    307       E -> K (in MLD; loss of enzymatic
FT                                activity; dbSNP:rs199476360).
FT                                {ECO:0000269|PubMed:19606494}.
FT                                /FTId=VAR_067417.
FT   VARIANT     308    308       G -> D (in MLD; late-infantile form;
FT                                dbSNP:rs199476356).
FT                                {ECO:0000269|PubMed:10477432}.
FT                                /FTId=VAR_054199.
FT   VARIANT     308    308       G -> V (in MLD; late-infantile form; no
FT                                enzyme residual activity;
FT                                dbSNP:rs199476356).
FT                                {ECO:0000269|PubMed:8891236}.
FT                                /FTId=VAR_054200.
FT   VARIANT     309    309       G -> S (in MLD; severe; 13% of normal
FT                                activity; dbSNP:rs74315459).
FT                                {ECO:0000269|PubMed:15326627,
FT                                ECO:0000269|PubMed:8101038}.
FT                                /FTId=VAR_007274.
FT   VARIANT     311    311       R -> Q (in MLD; juvenile-onset;
FT                                dbSNP:rs199476382).
FT                                {ECO:0000269|PubMed:7581401}.
FT                                /FTId=VAR_007275.
FT   VARIANT     312    312       E -> D (in MLD; low amounts of residual
FT                                enzyme activity; leads to a decreased
FT                                stability of the mutant enzyme;
FT                                dbSNP:rs199476390).
FT                                {ECO:0000269|PubMed:10751093}.
FT                                /FTId=VAR_054201.
FT   VARIANT     314    314       A -> T (in MLD; infantile-onset;
FT                                dbSNP:rs199476368).
FT                                {ECO:0000269|PubMed:9090526}.
FT                                /FTId=VAR_007276.
FT   VARIANT     325    325       G -> S (in MLD; juvenile-onset;
FT                                dbSNP:rs148092995).
FT                                {ECO:0000269|PubMed:14517960}.
FT                                /FTId=VAR_054202.
FT   VARIANT     327    327       T -> I (in MLD; late-infantile form).
FT                                {ECO:0000269|PubMed:10477432}.
FT                                /FTId=VAR_054203.
FT   VARIANT     335    335       D -> V (in MLD; late-infantile-onset;
FT                                loss of enzymatic activity;
FT                                dbSNP:rs74315475).
FT                                {ECO:0000269|PubMed:10381328,
FT                                ECO:0000269|PubMed:14517960,
FT                                ECO:0000269|PubMed:20339381,
FT                                ECO:0000269|PubMed:7581401,
FT                                ECO:0000269|PubMed:8723680}.
FT                                /FTId=VAR_007277.
FT   VARIANT     350    350       N -> S (associated with arylsulfatase A
FT                                pseudodeficiency; unknown pathological
FT                                significance; no effect on protein
FT                                abundance; loss of N-glycosylation;
FT                                dbSNP:rs2071421).
FT                                {ECO:0000269|PubMed:10477432,
FT                                ECO:0000269|PubMed:11941485,
FT                                ECO:0000269|PubMed:15026521,
FT                                ECO:0000269|PubMed:2574462,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_007278.
FT   VARIANT     356    356       F -> V (in dbSNP:rs6151422).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_018838.
FT   VARIANT     367    367       K -> N (in MLD; dbSNP:rs199476369).
FT                                {ECO:0000269|PubMed:9090526}.
FT                                /FTId=VAR_007279.
FT   VARIANT     370    370       R -> Q (in MLD; mild; dbSNP:rs74315477).
FT                                /FTId=VAR_007280.
FT   VARIANT     370    370       R -> W (in MLD; severe; no enzyme
FT                                residual activity; dbSNP:rs74315476).
FT                                {ECO:0000269|PubMed:18693274,
FT                                ECO:0000269|PubMed:7825603}.
FT                                /FTId=VAR_007281.
FT   VARIANT     376    376       Y -> N (in MLD; enzyme activity reduced
FT                                to 4.7% of wild-type enzyme;
FT                                dbSNP:rs199476344).
FT                                {ECO:0000269|PubMed:18693274}.
FT                                /FTId=VAR_054204.
FT   VARIANT     377    377       P -> L (in MLD; severe;
FT                                dbSNP:rs74315478).
FT                                {ECO:0000269|PubMed:10477432}.
FT                                /FTId=VAR_007282.
FT   VARIANT     381    381       D -> E (in MLD; early-infantile form;
FT                                dbSNP:rs6151425).
FT                                /FTId=VAR_054205.
FT   VARIANT     382    382       E -> K (in MLD; intermediate;
FT                                dbSNP:rs74315479).
FT                                {ECO:0000269|PubMed:20339381}.
FT                                /FTId=VAR_007283.
FT   VARIANT     384    384       R -> C (in MLD; dbSNP:rs199476370).
FT                                {ECO:0000269|PubMed:9090526}.
FT                                /FTId=VAR_007284.
FT   VARIANT     390    390       R -> Q (in MLD; juvenile-onset;
FT                                dbSNP:rs199476391).
FT                                {ECO:0000269|PubMed:20339381,
FT                                ECO:0000269|PubMed:9452102}.
FT                                /FTId=VAR_007285.
FT   VARIANT     390    390       R -> W (in MLD; late-infantile and
FT                                juvenile-onset; dbSNP:rs74315480).
FT                                {ECO:0000269|PubMed:18693274,
FT                                ECO:0000269|PubMed:20339381,
FT                                ECO:0000269|PubMed:7581401}.
FT                                /FTId=VAR_007286.
FT   VARIANT     391    391       T -> S (in dbSNP:rs743616).
FT                                {ECO:0000269|PubMed:10477432,
FT                                ECO:0000269|PubMed:11061266,
FT                                ECO:0000269|PubMed:11456299,
FT                                ECO:0000269|PubMed:11941485,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15326627,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:1670590,
FT                                ECO:0000269|PubMed:9888390,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_007287.
FT   VARIANT     397    397       H -> Y (in MLD; adult-onset;
FT                                dbSNP:rs199476376).
FT                                {ECO:0000269|PubMed:10381328,
FT                                ECO:0000269|PubMed:20339381,
FT                                ECO:0000269|PubMed:9452102}.
FT                                /FTId=VAR_007288.
FT   VARIANT     398    398       Missing (in MLD).
FT                                /FTId=VAR_007289.
FT   VARIANT     406    408       Missing (in MLD; late-infantile-onset).
FT                                {ECO:0000269|PubMed:9490297}.
FT                                /FTId=VAR_007290.
FT   VARIANT     406    406       S -> G (in MLD; loss of enzymatic
FT                                activity; dbSNP:rs199476361).
FT                                {ECO:0000269|PubMed:19606494}.
FT                                /FTId=VAR_067418.
FT   VARIANT     408    408       T -> I (in MLD; adult type;
FT                                dbSNP:rs28940895).
FT                                {ECO:0000269|PubMed:11456299}.
FT                                /FTId=VAR_054206.
FT   VARIANT     409    409       T -> I (in MLD; mild; dbSNP:rs74315481).
FT                                {ECO:0000269|PubMed:21265945,
FT                                ECO:0000269|PubMed:7909527}.
FT                                /FTId=VAR_054207.
FT   VARIANT     425    425       P -> T (in MLD; juvenile-onset; retains
FT                                about 12% of specific enzyme activity;
FT                                the mutant protein is unstable; results
FT                                in more rapid enzyme degradation in
FT                                lysosomes; addition of the cysteine
FT                                protease inhibitor leupeptin increases
FT                                the amount of the enzyme activity;
FT                                displays a modest reduction in the
FT                                octamerization process of the enzyme at
FT                                low pH; dbSNP:rs74315485).
FT                                {ECO:0000269|PubMed:10220151,
FT                                ECO:0000269|PubMed:12503099,
FT                                ECO:0000269|PubMed:12788103}.
FT                                /FTId=VAR_008133.
FT   VARIANT     426    426       P -> L (in MLD; juvenile/adult-onset;
FT                                mild; common mutation; dbSNP:rs28940893).
FT                                {ECO:0000269|PubMed:10381328,
FT                                ECO:0000269|PubMed:11941485,
FT                                ECO:0000269|PubMed:14517960,
FT                                ECO:0000269|PubMed:14680985,
FT                                ECO:0000269|PubMed:15326627,
FT                                ECO:0000269|PubMed:1670590,
FT                                ECO:0000269|PubMed:20339381,
FT                                ECO:0000269|PubMed:8095918}.
FT                                /FTId=VAR_007291.
FT   VARIANT     428    428       L -> P (in MLD; late-infantile form;
FT                                dbSNP:rs199476392).
FT                                {ECO:0000269|PubMed:18693274,
FT                                ECO:0000269|PubMed:9272717}.
FT                                /FTId=VAR_054208.
FT   VARIANT     429    429       Y -> S (in MLD; adult-onset;
FT                                dbSNP:rs199476380).
FT                                {ECO:0000269|PubMed:14517960}.
FT                                /FTId=VAR_054209.
FT   VARIANT     440    440       N -> S (in dbSNP:rs6151427).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_018839.
FT   VARIANT     464    464       A -> V. {ECO:0000269|PubMed:9888390}.
FT                                /FTId=VAR_007292.
FT   VARIANT     469    469       A -> G (in MLD; early-infantile form;
FT                                dbSNP:rs199476385).
FT                                {ECO:0000269|PubMed:14680985}.
FT                                /FTId=VAR_054210.
FT   VARIANT     489    489       C -> G (in MLD; late-onset;
FT                                dbSNP:rs199476388).
FT                                {ECO:0000269|PubMed:15026521}.
FT                                /FTId=VAR_054211.
FT   VARIANT     496    496       R -> H (in dbSNP:rs6151428).
FT                                {ECO:0000269|PubMed:9090526,
FT                                ECO:0000269|PubMed:9744473,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_007293.
FT   MUTAGEN      69     69       C->A: Abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:11124905}.
FT   MUTAGEN      69     69       C->S: Strongly decreases enzyme activity.
FT                                {ECO:0000269|PubMed:11124905}.
FT   CONFLICT    290    290       S -> P (in Ref. 5; AK098659).
FT                                {ECO:0000305}.
FT   STRAND       22     30       {ECO:0000244|PDB:1AUK}.
FT   HELIX        37     39       {ECO:0000244|PDB:1AUK}.
FT   HELIX        47     54       {ECO:0000244|PDB:1AUK}.
FT   STRAND       56     63       {ECO:0000244|PDB:1AUK}.
FT   STRAND       65     68       {ECO:0000244|PDB:1AUK}.
FT   HELIX        69     78       {ECO:0000244|PDB:1AUK}.
FT   HELIX        82     85       {ECO:0000244|PDB:1AUK}.
FT   HELIX       107    112       {ECO:0000244|PDB:1AUK}.
FT   TURN        113    115       {ECO:0000244|PDB:1AUK}.
FT   STRAND      117    122       {ECO:0000244|PDB:1AUK}.
FT   HELIX       130    132       {ECO:0000244|PDB:1AUK}.
FT   HELIX       136    139       {ECO:0000244|PDB:1AUK}.
FT   STRAND      142    146       {ECO:0000244|PDB:1AUK}.
FT   STRAND      153    155       {ECO:0000244|PDB:1AUK}.
FT   STRAND      159    162       {ECO:0000244|PDB:1AUK}.
FT   TURN        163    165       {ECO:0000244|PDB:1AUK}.
FT   STRAND      181    183       {ECO:0000244|PDB:1AUK}.
FT   STRAND      186    191       {ECO:0000244|PDB:1AUK}.
FT   HELIX       194    196       {ECO:0000244|PDB:1AUK}.
FT   HELIX       197    214       {ECO:0000244|PDB:1AUK}.
FT   STRAND      219    224       {ECO:0000244|PDB:1AUK}.
FT   STRAND      229    231       {ECO:0000244|PDB:1AUK}.
FT   TURN        236    241       {ECO:0000244|PDB:1AUK}.
FT   STRAND      242    244       {ECO:0000244|PDB:1AUK}.
FT   HELIX       245    267       {ECO:0000244|PDB:1AUK}.
FT   HELIX       271    273       {ECO:0000244|PDB:1AUK}.
FT   STRAND      274    282       {ECO:0000244|PDB:1AUK}.
FT   HELIX       286    291       {ECO:0000244|PDB:1AUK}.
FT   STRAND      304    306       {ECO:0000244|PDB:1AUK}.
FT   HELIX       307    310       {ECO:0000244|PDB:1AUK}.
FT   STRAND      315    317       {ECO:0000244|PDB:1AUK}.
FT   TURN        319    321       {ECO:0000244|PDB:1AUK}.
FT   STRAND      324    327       {ECO:0000244|PDB:1AUK}.
FT   HELIX       333    335       {ECO:0000244|PDB:1AUK}.
FT   HELIX       336    343       {ECO:0000244|PDB:1AUK}.
FT   HELIX       359    363       {ECO:0000244|PDB:1AUK}.
FT   STRAND      372    375       {ECO:0000244|PDB:1AUK}.
FT   TURN        382    384       {ECO:0000244|PDB:1AUK}.
FT   STRAND      387    391       {ECO:0000244|PDB:1AUK}.
FT   STRAND      394    400       {ECO:0000244|PDB:1AUK}.
FT   HELIX       404    406       {ECO:0000244|PDB:1AUK}.
FT   STRAND      408    410       {ECO:0000244|PDB:1E1Z}.
FT   HELIX       412    414       {ECO:0000244|PDB:1AUK}.
FT   STRAND      421    430       {ECO:0000244|PDB:1AUK}.
FT   TURN        431    433       {ECO:0000244|PDB:1AUK}.
FT   HELIX       450    469       {ECO:0000244|PDB:1AUK}.
FT   HELIX       477    479       {ECO:0000244|PDB:1AUK}.
FT   HELIX       483    485       {ECO:0000244|PDB:1AUK}.
FT   TURN        496    499       {ECO:0000244|PDB:1AUK}.
SQ   SEQUENCE   507 AA;  53588 MW;  3DDBE1378B4176A6 CRC64;
     MGAPRSLLLA LAAGLAVARP PNIVLIFADD LGYGDLGCYG HPSSTTPNLD QLAAGGLRFT
     DFYVPVSLCT PSRAALLTGR LPVRMGMYPG VLVPSSRGGL PLEEVTVAEV LAARGYLTGM
     AGKWHLGVGP EGAFLPPHQG FHRFLGIPYS HDQGPCQNLT CFPPATPCDG GCDQGLVPIP
     LLANLSVEAQ PPWLPGLEAR YMAFAHDLMA DAQRQDRPFF LYYASHHTHY PQFSGQSFAE
     RSGRGPFGDS LMELDAAVGT LMTAIGDLGL LEETLVIFTA DNGPETMRMS RGGCSGLLRC
     GKGTTYEGGV REPALAFWPG HIAPGVTHEL ASSLDLLPTL AALAGAPLPN VTLDGFDLSP
     LLLGTGKSPR QSLFFYPSYP DEVRGVFAVR TGKYKAHFFT QGSAHSDTTA DPACHASSSL
     TAHEPPLLYD LSKDPGENYN LLGGVAGATP EVLQALKQLQ LLKAQLDAAV TFGPSQVARG
     EDPALQICCH PGCTPRPACC HCPDPHA
//
